Randy Pardell, MD DLFAPA, FCTMSS
Randy I. Pardell, MD, DLFAPA, FCTMSS established Clearwave Mental Health with the goal of providing state-of-the-art, innovative, scientifically based psychiatric care for residents of the Greater Hudson Valley, New York. Dr. Pardell and his team evaluate each patient with an extensive medical and psychiatric history assessment. Genetic testing is used to customize medication selection based on an individual’s genetic profile. We offer Neurocognitive Testing to assist with diagnosis and treatment planning. Individualized treatment plans can include medication management, Transcranial Magnetic Stimulation Therapy (TMS is the breakthrough technology for treatment resistant depression, anxiety, OCD and smoking cessation), psychotherapy, esketamine therapy, nutritional evaluation and career consulting.
Ian A. Cook, MD, DLFAPA, FCTMSS
Dr. Cook has become professor emeritus at UCLA with his retirement from academia at the end of June, 2018. He continues to provide outstanding clinical care at the Los Angeles TMS Instutute and leads a new venture in the health IT space, HeartCloud.io as its CEO.
Most recently in academia, he had been the Chief Translational Innovation Officer at the UCLA Semel Institute for Neuroscience and Human Behavior. For many years he was a Professor-in-Residence in the Department of Psychiatry and Biobehavioral Sciences at the David Geffen School of Medicine at UCLA and in the Department of Bioengineering at the School of Engineering and Applied Science, and was a Research Scientist at the UCLA Semel Institute for Neuroscience and Human Behavior (formerly known as the UCLA Neuropsychiatric Institute) and the UCLA Brain Research Institute. His work had largely focused on the pathophysiology and treatment of neuropsychiatric conditions and disorders of complex human behavior.
Chronologically, Dr. Cook joined the faculty at UCLA in 1995, after his residency and research fellowship training. After a year as an Instructor, he advanced to Assistant Professor-in-Residence in 1996, to Associate Professor-in-Residence in 2003, to full Professor-in-Residence in 2010, and to Professor Emeritus in 2018.
In January 2007, Dr. Cook became the Founding Director of the UCLA Unipolar Depression Research and Clinic Program. In 2008 he was named the inaugural Joanne and George Miller and Family Professor in Depression Research, a term endowed chair at the UCLA Brain Research Institute.
Dr. Cook was one of the inventors of a new neuromodulation treatment, Trigeminal Nerve Stimulation (TNS), and in January 2008, became the first physician ever to administer TNS as a treatment for a psychiatric disorder (depression, and later PTSD). TNS is now also being studied for use in ADHD and other disorders.
Dr. Cook was the Founding Director of the Transcranial Magnetic Stimulation Treatment Service at UCLA, and in March 2009, he treated the first patient at UCLA with TMS, bringing that FDA-approved approach for treating depression to his program in Los Angeles. (video here). In 2013, he was elected to the Board of Directors of the newly-formed Clinical TMS Society, and in 2013 and 2014 served co-Chair of its Clinical Standards Committee and in 2017 joined its Legal, Business, and Ethics Committee, becoming Chair of the LBE Committee in 2018. From 2016 to 2018, he was appointed as a staff psychiatrist at the West Los Angeles VA Medical Center to mentor and support the growth of a TMS service at that facility. He also took part in the national roll-out of TMS and mentored VA practitioners at other facilities remotely via telepsychiatry.
He was an Attending Physician in the Resnick Neuropsychiatric Hospital; over his 20+ years on the UCLA faculty, he attended on the Adult Inpatient Service, in the General Outpatient and Mood Disorders Clinics, in the Adult Partial Hospital Program, on the Geriatric Inpatient ward, and on the Consultation-Liaison Psychiatry service at the UCLA Medical Center. Dr. Cook served as a psychiatric consultant to the UCLA Hand Transplantation Service since its inception until his retirement.
Dr. Cook has held numerous other leadership positions at UCLA and outside the University. At the David Geffen School of Medicine, he served as Chair of the Faculty of the School and of the Faculty Executive Committee (2011-2013). He was Chief of Staff of the Resnick Neuropsychiatric Hospital and chaired its Professional Staff Executive Committee (2011-2013).
He was named Chief Translational Innovation Officer (CTIO) for the Semel Institute in 2017, with a charge to facilitate and accelerate the identification, development, and commercialization of discoveries from the Semel Institute.
In the Department of Psychiatry, he previously served as Chair of the Curriculum Committee, and from 1996 to 2018, was Course Director for Psychiatry Grand Rounds, the longest-running Psychiatry Grand Rounds program on the web. For many years, he taught the modules on Major Depression and on Bipolar Disorder to UCLA medical students in their 2nd year neuroscience block, and taught Psychiatry residents in their Professionalism and Ethics course, their clinical neuroscience course, their outpatient psychopharmacology course, and in their Consultation-Liaison block (delirium). Outside the department, he taught Internal Medicine residents in their core curriculum about mood disorders in Primary Care. He has been honored with UCLA teaching awards on three occasions.
At the national level, Dr. Cook served on the Steering Committee on Practice Guidelines of the American Psychiatric Association from 1994 to 2008, and was a member of the Executive Committee from 2002 to 2008. The Practice Guidelines project of the APA develops and disseminates evidence-based guidelines for the evaluation and treatment of a range of psychiatric disorders. In 2011, he was tapped by Thomas Insel MD, then Director of the NIMH, to serve as a standing member of the Interventions Committee for Adult Disorders (ITVA), the Scientific Review Group at the NIH charged with reviewing scientific research applications addressing “pharmacotherapeutic, psychotherapeutic, somatic and combination treatments” in adults.
After having served as an external advisor for several years, in June 2014, Dr. Cook began a two-year sabbatical-like leave of absence from UCLA to serve as Senior Vice President and Chief Medical Officer of NeuroSigma, Inc., the life-sciences company that licensed his patents on trigeminal nerve stimulation from the Regents of the University of California. NeuroSigma has succeeded in achieving regulatory approval to make TNS available to patients in the European Union, Canada, and Australia, where it is marketed as the Monarch eTNS System® and in 2019 received US Food and Drug Administration clearance as a treatment for ADHD.
In the health information technology space, Dr. Cook has served as an advisor to health IT start-ups who are developing mobile applications that employ machine learning techniques to improve health care for brain disorders, such as Arctica Health. In July, 2018, he became a co-founder and CEO of a digital health start-up, HeartCloud.io with a focus on bringing the best in remote clinical care to practices throughout the United States..
Dr. Cook received his undergraduate degree from Princeton University and went to medical school at the Yale School of Medicine, before coming to UCLA for his residency at the UCLA/NPI and West LA VAMC psychiatry residency program and an NIMH research fellowship in psychobiology. After that, he joined the faculty.
His professional affiliations include being a Distinguished Fellow of the American Psychiatric Association and a board member of the Clinical TMS Society, as well as a member of the Society of Biological Psychiatry, the American Society of Clinical Psychopharmacology, the British Association for Psychopharmacology, the European College of Neuropsychopharmacology (corresponding member), and the International Society for ECT and Neurostimulation.
In addition to his work in academia, Dr. Cook has also volunteered to support a number of professional societies and organizations and has served as a consultant to the health care and entertainment industries as well as to the U.S. Department of Justice Civil Rights Division, and the U.S. Department of Defense about suicide prevention. He has volunteered to support a number of non-profit charitable organizations through board service. He is a life member of the National Eagle Scout Association.
Cindy Elkins was Executive Vice President and Chief Information Officer at Juno Therapeutics, one of the pioneers in CAR T blood cancer technology. Following two acquisitions, Cindy served as the Global Head CAR T Patient Experience at Bristol-Myers Squibb (BMS) where her team connected patients with their personalized therapy through world class service and technology.
Prior to Juno, Cindy was the VP, Pharma Informatics at Genentech-Roche responsible for all technology products/services across the Americas. In 2016, Genentech was ranked #3 in Computerworld’s “100 Best Places to Work in IT”. Before Genentech, Cindy was the VP and GM of Supplier Solutions at Ariba where she created the largest transacting business to business supplier community in the world.
Her daughter received SAINT TMS in early 2021, as a senior in high school, and benefited greatly from the experience. Cindy brings the voice of the parent and patient to FACTMS in hopes of bringing this amazing treatment to more adolescents around the world.
Ms Elkins is currently a Non-Executive Director at Chimeric Therapeutics (ASX:CHM), a Board Trustee at Vitalant and Board Co-Chair of the Foundation for Art and Healing.
She received her BS in Applied Mathematics from UCLA and her MBA from Santa Clara University.
Kevin Kinback, MD, FCTMSS
Graduating from Loma Linda University Medical School in 1992, Dr. Kinback trained in psychiatry at Loma Linda, was Chief Resident, and remains on the faculty as Assistant Clinical Professor of Psychiatry. He began private practice in Mission Viejo in 1995. Dr. Kinback was one of the very first psychiatrists in the country to offer TMS in 2009, and with a keen interest in cutting-edge medicine, he founded Advanced TMS Center. Specializing in Transcranial Magnetic Stimulation (TMS) therapy for treatment-resistant depression, Dr. Kinback has done thousands of TMS treatments. He is certified on 3 different TMS devices, with a first-class office including electronic medical records, patient & peer portals, genetic testing for personalized prescribing, digital documents, telehealth, EKG & lab services. Dr. Kinback brings high quality TMS therapy to Orange County, and is both a founding member and leader in the Clinical TMS Society. He served on the Clinical TMS Society Board for 8 years, serving on many committees, as Treasurer, and Chaired the Insurance Committee as a strong advocate in the fight for universal insurance coverage for TMS.
Mohamed Abdelghani, MBBCh, MSc, FRCPsych, FCTMSS
Dr Mohamed Abdelghani is one of the best known psychiatrists in London who specialises in treating depression. He is credited for being one of the driving forces introducing innovative evidence-based treatment to clinical practice in the UK.
Dr Abdelghani is currently serving as the President of the Clinical TMS Society (CTMSS). The CTMSS is the largest TMS professional association in the world. The work of the society is dedicated to optimising clinical practice, awareness, and accessibility of Transcranial Magnetic Stimulation therapy. He is the first person from outside the USA to be elected to this position and before that he served in various leadership positions in the CTMSS. He was Vice-President of the society for a year, Secretary for 2 years and has been a member of the Board of Directors of the society since 2017.
In 2016, Dr Abdelghani founded the first clinical TMS service in the NHS in London and South England at Camden and Islington NHS Foundation Trust and he continues to lead this service until the present time. He has been formally trained in TMS at two of the top TMS centres in the world; Harvard University in USA and Medical University of South Carolina (MUSC).
Dr Abdelghani established his private practice, Dyad Medical, in Harley Street in London in 2015. In 2020 he expanded his private practice by adding two new services; London TMS Centre and London Esketamine Clinic. Through these two new services his team offers TMS and Esketamine to private patients who suffer with treatment-resistant or difficult to treat depression. In 2020 he became the first psychiatrist in the UK to treat a patient using Esketamine nasal spray in the private sector. His innovative work also included treating patients suffering with Alzheimer’s disease using Transcranial Pulse Stimulation (TPS). He did this through creating an Old Age clinical pathway in Dyad Medical in 2022 under the name, London Alzheimer’s Clinic. Dyad Medical was the first place in the UK to offer this novel treatment to patients suffering with Alzheimer’s disease.
Dr Abdelghani has been working as a Consultant Psychiatrist in the NHS since 2013. He has been a consultant psychiatrist at Camden & Islington NHS Foundation Trust in Central London since 2014. He holds two clinical excellence awards from the Trust for his work on improving NHS services and providing high quality care. Dr Abdelghani completed his post-graduate psychiatric training at South London & Maudsley NHS Foundation trust (SLaM) which is the biggest mental health trust in the UK, a centre of excellence and one of the most influential mental health organisations in the world. After finishing his higher psychiatry training at SLaM he worked as a consultant psychiatrist for almost a year at the same organisation before taking on his current post at Camden & Islington NHS Foundation Trust with the aim of developing highly specialised depression services.
Dr Abdelghani is actively involved in TMS clinical research with the aim of making TMS treatment more efficient and more accessible to different groups of patients. He was the London Principal Investigator for the BRIGhTMIND TMS Randomised Control Trial (RCT).
In 2009 Dr Abdelghani became a member of the Royal College of Psychiatrists, in 2012 he obtained MSc in Clinical Neuroscience from King’s College London, in 2020 he was elected to become a fellow of the Royal College and 2022 he was awarded the fellowship of the Clinical TMS Society.
Kimberly Cress, MD
Bio Coming Soon
Diana Daniele is a journalist and literary publicist living in Los Angeles. She writes frequently about mental health, invisible illness, female friendship, and family dynamics for publications like Newsweek, Insider, Zibby Magazine, and Brevity. Diana is currently at-work on a memoir entitled DAMN, GIRL: A Miraculous Memoir, which chronicles her four-year mental health odyssey, and which culminates in her ultimate healing via Transcranial Magnetic Stimulation or TMS. A tireless mental health advocate, Diana is a member of the Board’s Patient Advocacy Group (PAG), which aligns with one of the pillars of her book’s platform, which is to see the FDA approve TMS for those under the age of 18. Diana has appeared on FOX-TV and ABC-TV to share her TMS story, as well as on numerous podcasts. Diana is also a sought-after speaker on mental health for conferences, symposiums, and book festivals.
Diana’s career began while she was earning her master’s degree from the Annenberg School of Communication & Journalism at the University of Southern California. She won a Research Grant to study “How Barbie Speaks Sexually to Children,” which she completed at USC’s Institute for the Study of Women and Men (ISWM), a feminist think tank studying how women’s gender roles are portrayed in film and on television. When her research was complete, Ms. Daniele stayed on at ISWM, working with both the media and corporate sponsors, such as Paramount Pictures, DreamWorks, and NBC/Universal.
A sought-after publicist for luxury brands and icons, Diana counts among her current and past clients: Saks Fifth Avenue, Ralph Lauren, AMC Theatres, The Palm restaurants, Rock the Vote, Elizabeth Glaser Pediatrics AIDS Foundation, and the Beverly Hills Hotel. Previously, Diana organized events at the United States Embassy’s Cultural Center in Madrid, Spain. She started her career as a broadcast news journalist at NBC-LA and Entertainment Tonight.
A Phi Beta Kappa graduate of the University of California, Los Angeles, Diana earned her M.A. in Journalism from the Annenberg School for Communication and Journalism at USC. She has completed coursework in English Literature at University of Cambridge, England and studied philology at the University of Madrid, Complutense.
Mark S. George, MD
Mark S. George, MD received his medical degree from the Medical University of South Carolina (MUSC) in Charleston in 1985, where he continued with dual residencies and board certification in both neurology and psychiatry.
He completed serial research fellowships focusing on brain imaging (PET, SPECT, MRI) and the then new field of brain stimulation. In 1990 at Queen Square London, he wandered into John Rothwell’s laboratory, after hearing about transcranial magnetic stimulation (TMS) from a patient in the elevator. Later while at the Biological Psychiatry Branch of the National Institute of Mental Health in Bethesda, MD he performed pioneering imaging, healthy volunteer and patient studies with prefrontal TMS, launching it to its now widespread research and clinical use.
Specifically 1993 while at the NIMH, he discovered that daily prefrontal rTMS over several weeks could treat depression and ever since he has worked to grow the science of TMS, both in terms of how it works in the brain, and in critically evaluating its therapeutic applications, especially in treating depression.
He returned to MUSC in 1996 and started the research imaging center, which he led until 2007. In June 1998 at MUSC, he also helped pioneer another new treatment for resistant depression, cervical vagus nerve stimulation (VNS). This was FDA approved in 2006.
Dr. George is thus a world expert in brain imaging and brain stimulation, particularly combining the two. Clinically he is an expert on depression and several other neuropsychiatric disorders. He is the editor-in-chief of a new journal he launched with Elsevier in 2008 called, Brain Stimulation: Basic, Translation and Clinical Research in Neuromodulation. He has served as the chief editor for over 15 years now and this journal is the top in its field. He has published over 500 scientific articles or book chapters, and has written or edited 6 books, several with multiple editions.
He has been continuously funded by NIH and other funding agencies since his fellowships and has received many international awards.
Mark S. George, MD
Distinguished University Professor of Psychiatry, Radiology and Neuroscience
Layton McCurdy Endowed Chair, Director, Brain Stimulation Division
Editor-in-Chief, Brain Stimulation: Basic, Translational and Clinical Research in Neuromodulation
502 North, Institute of Psychiatry
67 President St.
Charleston, SC 29425
843 876 5142
Staff Psychiatrist, Ralph H. Johnson VA Medical Center, Charleston
Todd Hutton MD, DLFAPA, FCTMSS
Todd Hutton MD, DLAPA
Dr. Todd Hutton is the founder and Medical Director of Southern California TMS Center and has been practicing TMS since 2009. He has been an active leader in the Clinical TMS Society and served as its President in 2019-2020. He and teaches and lectures internationally on TMS, is a regular member of the Society’s PULSES faculty, and has published research on TMS. He is a Board-Certified psychiatrist, an Adjunct Clinical Professor of Psychiatry at the USC Keck School of Medicine, and a Distinguished Life Fellow of the American Psychiatric Association.
Martha Koo, MD, LFAPA, FCTMSS
Dr. Martha B. Koo, M.D., DLFAPA, FCTMSS
A pioneer in the development and application of Transcranial Magnetic Stimulation (TMS), Dr. Koo opened the South Bay TMS Therapy Center in 2009, and she was a founding member of the Clinical TMS Society (CTMSS). She currently serves on the CTMSS Board of Directors and the Executive Council as VP-President Elect. Dr. Koo completed undergraduate studies at Princeton University and medical training at the UCLA David Geffen School of Medicine. She obtained psychiatry residency training at the UCLA Resnick Neuropsychiatric Institute and subsequent psychoanalytic training at the New Center for Psychoanalysis. Dr. Koo is Board Certified in Psychiatry and in Addiction Medicine. The South Bay TMS Center evolved into the Neuro Wellness Spa, where Dr. Koo is Founding CEO. Neuro Wellness Spa is an in-network psychiatry practice with six outpatient clinics across the greater LA area that offer medication management, TMS and ketamine therapy. Additionally, Dr. Koo is the Medical Director at Clear Recovery Center, which provides the full continuum of in-network behavioral health treatment— from detox, dual diagnosis and mental health residential programs to outpatient treatment (PHP, IOP & OP) for teens and adults. Dr. Koo is the author of several peer-reviewed articles on the application and efficacy of TMS. Dr. Koo is a distinguished Fellow of the CTMSS and the American Psychiatric Association. With a strong background in human psychodynamics, psychological theory, psychiatric medicine, and neuroscience, Dr. Koo has dedicated her career to community, academic and professional advocacy for the advancement of psychiatric treatment and to increase access and awareness to the most effective, personalized mental health interventions.
Kristin Raj, MD
Kristin Raj, MD
Dr. Raj specializes in the treatment of mood disorders with an expertise in neuromodulation and in the psychopharmacological management of bipolar disorder. She is co-chief of the mood disorders section and chief of the bipolar clinic. She is the director of education for interventional psychiatry where she manages resident education in ECT and TMS and development of didactics. She is also co-director of the neuroscience curriculum for the psychiatry residency where she has worked to assess and create a new series of interactive lectures. She currently serves on the Board of Directors and the Education Committee of the Clinical TMS society. She is on the Education Committee of the National Neurosciences Curriculum Initiative.
Robert A. Sammons, MD, PhD
Dr. Bob Sammons received a bachelor’s and master’s degree from Auburn University, a Ph.D. in clinical psychology from the University of North Carolina at Greensboro, and a medical degree from the University of North Carolina at Chapel Hill. He does not confuse his football team with his basketball team. He did a residency in psychiatry at the University of Virginia as well as a forensic psychiatry fellowship. While a Captain in the Air Force he helped set up and run the treatment phase of the Air Force Drug Treatment program in1971. He has practiced adult psychiatry in Grand Junction for over 35 years. He received training in Transcranial Magnetic Stimulation in 2006 from Dr. Alvaro Pascual-Leone, from Dr. Mark George in 2017 and returned to Harvard for Dr. Pascual-Leone’s intensive course in TMS in 2018. He is Medical Director for TMS Solutions with ten TMS offices in various locations in the West. He is on the national Clinical TMS Society Board of Directors, and recently served as member-at-large on the Executive Committee. He has been a member of the Outreach, Education, Legal, Business and Ethics, and Annual Meeting committees and served as Chairman of the 2023 Annual Meeting. He is on the Board of Directors for the Foundation for the Advancement of Clinical TMS. He was on the faculty of the Pulses Course. He is a Fellow in the Clinical TMS Society and received the Legacy Award at the 2023 annual meeting. He has been known to cook a little BBQ
Baron Short, MD, MSCR
Dr. Short completed his residency training in internal medicine and psychiatry at the Medical University of South Carolina (MUSC) in 2006. Dr. Short completed his M.S.C.R. in 2009 at MUSC with a focus on brain stimulation in psychiatric disorders. He is an associate professor in the departments of psychiatry and medicine at MUSC and is currently the Medical Director of the Brain Stimulation Service at MUSC since 2010. He directs the clinical and educational delivery of brain stimulation (ECT, TMS, VNS, DBS) for neuropsychiatric disorders at MUSC. He is an investigator in several brain stimulation clinical trials employing FEAST (Focal Electrically Administered Seizure Therapy), TMS, EpCS, and DBS for refractory depression. He is involved in advocacy about TMS, including work as co-chair with the CTMSS Insurance Committee, subcommittee on NICE guidelines, and podcasts to educate the public on this life-saving treatment.
Rick Trautner, MD
Dr. Trautner is a Board-Certified Psychiatrist who received his undergraduate degree in English Literature from UC Irvine and his MD from Case Western Reserve University. He did his Psychiatry Residency at UCLA Neuropsychiatric Institute and had additional training at the Los Angeles Psychoanalytic Institute. His work has included a variety of settings including psychiatric hospitals and outpatient clinics. In addition, he has held a number of leadership roles including President of Bay Psychiatric Associates in Berkeley, California and Medical Director and Chair of the Department of Psychiatry at numerous facilities. Dr. Trautner has served on the teaching faculty of the UCLA Psychiatry Residency program and at UC Berkeley Extension. In order to bring an innovative new treatment to his community, he founded the TMS service at Bay Psychiatric Associates in 2009 and served as the Director of Interventional Services. He was a founding Director of the Clinical TMS Society and served as Secretary and Treasurer as well as on its Executive Committee for several terms. Dr. Trautner has received numerous awards for his clinical and administrative work and is a Fellow of the American Psychiatric Association and the Clinical TMS Society.